RxDoctor Payments Data

Jayanti Panchal, MD

Internal Medicine · Ocala, FLNPI 1164458758

Payments from drug & device makers

$72,581in general payments, 2019–2025

Across 530 payments — averaging $136.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$40K
  • AbbVie$18K
  • Bayer$7K
  • GSK$1K
  • Ironwood Pharmaceuticals, Inc$653
  • Phathom Pharmaceuticals, Inc.$572
  • plus $6K from 41 others

What the payments were for

  • Consulting fees$3000%
  • Speaking & faculty fees$59,49082%
  • Travel & lodging$5541%
  • Food & beverage$12,07217%
  • Education$1650%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$72,581 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$798,505
Medicare patients
730
Services billed
31,787

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban144$164,689
EliquisApixaban194$105,179
JardianceEmpagliflozin61$81,144
EntrestoSacubitril/Valsartan65$72,789
OzempicSemaglutide50$68,297
TrulicityDulaglutide43$52,871
JanuviaSitagliptin Phosphate48$35,814
MounjaroTirzepatide30$30,673
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$26,997
FarxigaDapagliflozin Propanediol28$26,779
LinzessLinaclotide14$17,693
Tresiba Flextouch U-100Insulin Degludec18$15,352
VascepaIcosapent Ethyl23$13,795
Tresiba Flextouch U-200Insulin Degludec15$10,238
Breo ElliptaFluticasone/Vilanterol12$10,206

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$39,638$164,689144 claims
PfizerEliquis$234$105,179194 claims
Boehringer IngelheimJardiance, Jentadueto$132$88,43072 claims
Lilly USA, LLCTrulicity, Mounjaro$263$83,54573 claims
NovartisEntresto$177$72,78965 claims
Novo NordiskOzempic$444$68,29750 claims
GSKTrelegy Ellipta, Breo Ellipta$1,272$37,20344 claims
MerckJanuvia$91$35,81448 claims
AstraZenecaFarxiga$476$26,77928 claims
AbbVieLinzess, Synthroid$17,779$21,48050 claims
Sanofi-aventis U.S. LLCMultaq$81$9,72112 claims
Kowa Pharmaceuticals America, Inc.Livalo$101$5,56435 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Ocala

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →